| Literature DB >> 35237603 |
Dan Song1, Manman Li1, Xue Yu1, Yuqin Wang1, Jiaying Fan1, Wei Yang1, Liming Yang2, Hong Li1.
Abstract
Atherosclerosis (AS) is a chronic inflammatory disease seriously endangering human health, whose occurrence and development is related to many factors. Pyroptosis is a recently identified novel programmed cell death associated with an inflammatory response and involved in the formation and progression of AS by activating different signaling pathways. Protein modifications of the sirtuin family and microRNAs (miRNAs) can directly or indirectly affect pyroptosis-related molecules. It is important to link atherosclerosis, thermogenesis and molecular modifications. This article will systematically review the molecular pathways of pyroptosis in AS, which can provide a new perspective for AS prevention and treatment.Entities:
Keywords: AMPK; MAPK; NF-κB; SIRT; atherosclerosis; miRNA; pyroptosis
Year: 2022 PMID: 35237603 PMCID: PMC8884404 DOI: 10.3389/fcell.2022.824165
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1The canonical pathway and non-canonical pathway of pyroptosis. Pyroptosis is a novel pro-inflammatory regulator of cell death. Depending on the key molecular patterns involved in the activation and execution steps, they can be divided into the canonical pathway and non-canonical pathway. In the caspase1-dependent pyroptosis pathway, cells can activate inflammatory vesicles to trigger pyroptosis in response to multiple factors, activating the respective inflammatory vesicles (including NLRP3, AIM2 or pyrin) through the action of PAMPs and DAMPs; NLRP3 recruits ASC and pro-caspase-1 through various pathways, causing activation of caspase-1 and maturation and secretion of pro-inflammatory cytokines such as IL-1β and IL-18. GSDMD-N is formed by the cleavage of inflammatory cystathione, triggering the rupture of cell membranes and promoting the release of inflammatory factors, cell swelling and pytoptosis. In the non-canonical pathway, the Gram-negative bacterial cell wall fraction LPS activates caspase 4/5/11, which mediates pyroptosis by directly triggering pyroptosis through the cleavage of GSDMD. NLRP3: NOD-like receptor protein 3; AIM2: in melanoma 2; PAMPs: pathogen-associated molecular patterns; DAMPs: danger-associated molecular patterns; GSDMD: gasdermin D; LPS: lipopolysaccharide.
FIGURE 2Relationship between SIRT1 and pyroptosis pathway in atherosclerosis in macrophages. Ox-LDL and CC- in atherosclerotic lesions activates NF-κβ in macrophages with NLRP3 inflammatory vesicle initiation and NLRP3 inflammatory vesicle activation, promoting the inflammatory factor IL-18/IL-1β, leading to cytoplasmic swelling and membrane rupture, resulting in the release of inflammatory factors and promoting the onset of pyroptosis. At the same time, ox-LDL inhibits the expression of SIRT1, which further leads to the activation of NF-κβ, and this vicious circle will further aggravate the development of AS. ox-LDL: oxidatively modified low-density lipoprotein; NF-κβ: nuclear factor kappa-light chain-enhancer of activated B.
miRNA involved in the regulation of pyroptosis-related molecules.
| miRNA | Model | Signaling pathways/Target | Result | References |
|---|---|---|---|---|
| miR-20a | Human aortic endothelial cells (HAECS) | TLR、TXNIP | Negatively regulates TLR4 and NLRP3 signaling to protect HAECs from inflammatory injuries, inhibits the atherosclerotic development |
|
| miR-30c-5p | HAECs | FOXO3 | Inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis, anti-atherosclerosis |
|
| miR-125a-5p | Human umbilical vein endothelial cells | TET2 | Activates NLRP3 inflammasome and caspase-1, promotes pyroptosis and atherosclerosis progression |
|
| Human vascular smooth muscle cells | CCL4 | Inhibits expression of NLRP3、ASC、caspase-1 and IL-1β proteins, anti-atherosclerosis |
| |
| miR-223 | Primary macrophages | NLRP3 | Inhibits NLRP3 inflammasome |
|
| miR-9 | Human THP-1 derived macrophages | JAK1/STAT1 | Inhibits activation of the NLRP3 inflammasome, attenuates atherosclerosis-related inflammation |
|
| miR-181a | THP‐1 macrophages | MEK1 | Inhibits the expression of NLRP3 inflammasome-related proteins, alleviates pyroptosis |
|
| miR-33 | Bone marrow derived macrophages, Ldlr
| Prkaa1 | Promotes pyroptosis and atherosclerosis progression |
|
| miR-155 | THP-1 macrophages, ApoE−/- mice | ERK1/2 | Increases the expression of NLRP3 inflammasome and the secretion of IL-1β and IL-18, aggravates the carotid atherosclerosis lesion |
|
| miR-145 | Vascular smooth muscle cells, ApoE−/- mice | CD137/NFATc1 | Inhibits NLRP3 inflammasome and pyroptosis, increases the stability of atherosclerosis lesions |
|
TLR, toll-like receptors; TXNIP, thioredoxin-interacting protein; FOXO3, Forkhead box O3; TET, ten-eleven translocation; CCL4, C-C motif chemokine 4-like; JAK1, Janus kinase 1; MEK1, MAP, kinase 1; Prkaa1, AMP, kinase; NFATc1, nuclear factor of activated T cells1.